Shares of CA-based glucose monitoring systems provider
) have climbed nearly 14.6% since the announcement of its
encouraging 2014-second quarter results last week followed by the
revelation of its data integration relationship with Silicon
Valley-based manufacturer of Asante Snap Insulin Pump, Asante
Dexcom collaborated with privately-held Asante to integrate insulin
data from the Asante Snap Insulin Pump into its mobile app platform
to facilitate simplified diabetes management. The platform provides
timely and accurate data, supporting effective diabetes control for
DexCom's first-of-its-kind mobile app platform, designed to
aggregate glucose and other diabetes-related data from patients'
devices and display the integrated data on a smart phone, is
currently under development.
Asante Snap Insulin Pump is the second insulin delivery device to
be integrated into the Dexcom mobile app, the first being Insulet
) OmniPod System. Notably, DexCom's mobile app platform will
provide Insulet's OmniPod users a wider access to data, thus
improving diabetes administration. It will also help diabetic
people achieve better control on their disease.
Earlier, in June, DexCom disclosed its intentions to adopt an "open
architecture" approach to diabetes-related data. The approach will
include an "approved by DexCom" indication to validate the
authenticity of devices and apps integrating DexCom CGM data.
DexCom posted a narrower loss of $7.0 million or 10 cents per share
in the second quarter of 2014 compared with $10.1 million or 14
cents in the comparable quarter of 2013. The loss was in line with
the Zacks Consensus Estimate.
DexCom's total revenues escalated 64.2% to $58.8 million, topping
the Zacks Consensus Estimate of $53.0 million. The upside was
driven by a significant 63.9% rise in product revenues to $58.2
million and 100% growth in development grant and other revenues to
Moreover, DexCom exited the quarter with a higher cash balance of
$49.5 million as of Jun 30, 2014, compared with $43.2 million as of
Dec 31, 2013. Also, the total long-term debt went down 14.7% to
$5.8 million from $6.8 million as of Dec 31, 2013.
Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked
stocks in the medical instruments sector include Alphatec Holdings,
) and RTI Surgical Inc. (
) Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
DEXCOM INC (DXCM): Free Stock Analysis Report
ALPHATEC HLDGS (ATEC): Free Stock Analysis
INSULET CORP (PODD): Free Stock Analysis Report
RTI SURGICAL (RTIX): Free Stock Analysis Report
To read this article on Zacks.com click here.